Littleton, CO (PRWEB) January 08, 2015
CereScan Corp. and its wholly-owned subsidiary, Molecular Imaging of Colorado, have been awarded a three-year term of accreditation in PET/CT as the result of a recent review by the American College of Radiology (ACR). PET/CT is a subset of medical imaging that uses safe amounts of radioactive material, to diagnose a variety of diseases, including many types of cancers, heart disease, and other abnormalities within the body and brain.
The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities satisfying the ACR Practice Guidelines and Technical Standards after a thorough review by independent, board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, facility equipment, quality control procedures, and quality assurance programs are all assessed. The findings are reported to the ACR Committee on Accreditation, which subsequently provides the facility with a comprehensive report they can use for continuous practice improvement.
“ACR accreditation confirms the quality and validity of our PET/CT imaging procedures and will give our patients, referring physicians, and research partners confidence that we are following the best practices in medical imaging,” said John Kelley, Chairman and CEO of CereScan. “This accreditation provides the keystone for the launch of Molecular Imaging of Colorado, which will provide PET/CT services to cancer patients. In addition, PET/CT will give us another sophisticated tool for the diagnosis of brain disorders by measuring metabolism in the brain. This capability complements our years of experience measuring blood flow in the brain with SPECT imaging.”
The ACR is a national organization serving more than 36,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services.
Molecular Imaging of Colorado is based in Littleton and is a wholly-owned subsidiary of CereScan. MIC will offer PET/CT imaging services to the patients of Oncologists, Pulmonologists, and Urologists and any others who may need diagnostic imaging. To schedule an appointment or for more information, please call 303-954-4957.
CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:
- Traumatic Brain Injury
- Toxic Brain Injury
- Alzheimer’s Disease
- Mild Cognitive Impairment
- Other Dementias
- Parkinson’s Disease
- Obsessive Compulsive Disorder
- Bipolar Disorder
- Anxiety Disorder
CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.